215 related articles for article (PubMed ID: 30170756)
1. Correspondence between symptoms and preference-based health status measures in the STOP study.
Gold LS; Patrick DL; Hansen RN; Beckett V; Goss CH; Kessler L
J Cyst Fibros; 2019 Mar; 18(2):251-264. PubMed ID: 30170756
[TBL] [Abstract][Full Text] [Related]
2. Correspondence between lung function and symptom measures from the Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score (CFRSD-CRISS).
Gold LS; Patrick DL; Hansen RN; Goss CH; Kessler L
J Cyst Fibros; 2019 Nov; 18(6):886-893. PubMed ID: 31126901
[TBL] [Abstract][Full Text] [Related]
3. A prospective randomised controlled mixed-methods pilot study of home monitoring in adults with cystic fibrosis.
Nash EF; Choyce J; Carrolan V; Justice E; Shaw KL; Sitch A; Mistry H; Whitehouse JL
Ther Adv Respir Dis; 2022; 16():17534666211070133. PubMed ID: 35274585
[TBL] [Abstract][Full Text] [Related]
4. Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis.
Solem CT; Vera-Llonch M; Liu S; Botteman M; Castiglione B
Health Qual Life Outcomes; 2016 Apr; 14():63. PubMed ID: 27097977
[TBL] [Abstract][Full Text] [Related]
5. A prospective pilot study of home monitoring in adults with cystic fibrosis (HOME-CF): protocol for a randomised controlled trial.
Choyce J; Shaw KL; Sitch AJ; Mistry H; Whitehouse JL; Nash EF
BMC Pulm Med; 2017 Jan; 17(1):22. PubMed ID: 28114922
[TBL] [Abstract][Full Text] [Related]
6. Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis.
VanDevanter DR; Heltshe SL; Spahr J; Beckett VV; Daines CL; Dasenbrook EC; Gibson RL; Raksha J; Sanders DB; Goss CH; Flume PA;
J Cyst Fibros; 2017 Sep; 16(5):607-615. PubMed ID: 28438499
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
[TBL] [Abstract][Full Text] [Related]
8. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.
West NE; Beckett VV; Jain R; Sanders DB; Nick JA; Heltshe SL; Dasenbrook EC; VanDevanter DR; Solomon GM; Goss CH; Flume PA;
J Cyst Fibros; 2017 Sep; 16(5):600-606. PubMed ID: 28457954
[TBL] [Abstract][Full Text] [Related]
9. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis.
Hoppe JE; Wagner BD; Accurso FJ; Zemanick ET; Sagel SD
J Cyst Fibros; 2018 Nov; 17(6):760-768. PubMed ID: 29921503
[TBL] [Abstract][Full Text] [Related]
11. Predicting return of lung function after a pulmonary exacerbation using the cystic fibrosis respiratory symptom diary-chronic respiratory infection symptom scale.
Gill ER; Goss CH; Sagel SD; Wright ML; Horner SD; Zuñiga JA
Res Sq; 2023 Sep; ():. PubMed ID: 37790510
[TBL] [Abstract][Full Text] [Related]
12. The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis.
VanDevanter EJ; Heltshe SL; Skalland M; Lechtzin N; Nichols D; Goss CH
J Cyst Fibros; 2021 Nov; 20(6):932-936. PubMed ID: 33685776
[TBL] [Abstract][Full Text] [Related]
13. Association between elevated peripheral blood eosinophil count and respiratory outcomes in adults with cystic fibrosis.
Ye SC; Desai S; Karlsen E; Kwong E; Wilcox PG; Quon BS
J Cyst Fibros; 2022 Nov; 21(6):1048-1052. PubMed ID: 35370086
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.
Thornton CS; Caverly LJ; Kalikin LM; Carmody LA; McClellan S; LeBar W; Sanders DB; West NE; Goss CH; Flume PA; Heltshe SL; VanDevanter DR; LiPuma JJ
Ann Am Thorac Soc; 2024 Apr; 21(4):595-603. PubMed ID: 37963297
[No Abstract] [Full Text] [Related]
15. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.
Hernandez G; Garin O; Dima AL; Pont A; Martí Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M;
J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744
[TBL] [Abstract][Full Text] [Related]
16. Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment.
VanDevanter DR; Heltshe SL; Sanders DB; West NE; Skalland M; Flume PA; Goss CH;
J Cyst Fibros; 2021 Jan; 20(1):36-38. PubMed ID: 32800708
[TBL] [Abstract][Full Text] [Related]
17. Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany.
Eidt-Koch D; Mittendorf T; Greiner W
BMC Pediatr; 2009 Aug; 9():55. PubMed ID: 19715563
[TBL] [Abstract][Full Text] [Related]
18. Patient-Reported Outcome Measures for Symptom Perception During a Cystic Fibrosis Exacerbation.
Schmid-Mohler G; Caress AL; Spirig R; Benden C; Yorke J
Respir Care; 2018 Mar; 63(3):353-366. PubMed ID: 29317460
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis.
Wagener JS; Williams MJ; Millar SJ; Morgan WJ; Pasta DJ; Konstan MW
J Cyst Fibros; 2018 Jul; 17(4):496-502. PubMed ID: 29685810
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality-of-life in children with cystic fibrosis aged 5-years and associations with health outcomes.
Cheney J; Vidmar S; Gailer N; Wainwright C; Douglas TA;
J Cyst Fibros; 2020 May; 19(3):483-491. PubMed ID: 32165156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
